Get the Daily Brief
Latest Biotech News
Targeted-genomics diagnostics expand in transplant care and prostate surveillance
Verici Dx validated a pre-transplant kidney rejection risk test built around a 29-gene RNA expression immune signature. The assay, Pre-Transplant Risk Assessment (PTRA), was confirmed in a...
Obesity pipeline acceleration in China and IPO funding
Kailera reported early Phase 1 results for KAI-4729, a triple-acting obesity investigational therapy developed in collaboration with Hengrui Pharmaceuticals. In the China study, Kailera said...
Atopic dermatitis therapy advances toward Phase 3 with Blackstone non-dilutive funding
Apogee Therapeutics secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences to move zumilokibart into Phase 3 development for atopic dermatitis. The funding deal is tied...
FDA decision delay for AstraZeneca’s camizestrant in breast cancer
The FDA delayed its decision on AstraZeneca’s oral SERD camizestrant after an advisory committee vote turned down the drug for certain advanced breast cancer indications. The company said the...
CAR-T trial expansion in China
Waypoint Bio raised $20 million in Series A funding to run three CAR-T trials in China, using the country’s clinical testing environment to advance cell therapy candidates. The company described...
Regulatory and policy friction around biopharma dealmaking with China
Washington’s debate over outbound investment curbs broadened after a letter from Rep. John Moolenaar urged the Treasury Department to classify biotechnology under the COINS Act of 2025’s...
Protein analytics and modeling: next-gen precision genomics for cancer
University of California San Diego researchers introduced MutationProjector, an AI-enabled tumor genome foundation model designed to map mutational co-dependencies and predict therapy response....
Biotech sentiment and funding expectations
A new Biopharma Sentiment Index update reported a rebound in headline conditions during Q2 2026, with the overall score rising to 96 from 90 in Q1. The measure also showed hiring resilience and...
Apogee Therapeutics taps Blackstone non-dilutive capital for Phase 3 push in atopic dermatitis
Apogee Therapeutics moved to accelerate its late-stage atopic dermatitis program after securing up to $1.3 billion in non-dilutive funding from Blackstone Life Sciences. The capital is earmarked...
AI drug discovery pivots after ALS trial failure at Verge/Verge Labs
Verge Genomics rebranded as Verge Labs after it reported disappointing results from an early-stage clinical trial of VRG50635, an AI-designed ALS therapy targeting PIKfyve. The company said the...
FDA extends review of AstraZeneca’s camizestrant after advisory committee vote
The FDA pushed back its decision date on AstraZeneca’s oral SERD camizestrant for certain advanced breast cancer patients following a negative outcome from an FDA advisory committee. AstraZeneca...
Kailera’s triple-hormone obesity drug posts early Phase 1 weight-loss results via Hengrui
Kailera reported double-digit weight loss from its investigational “triple-G” obesity shot in an early Phase 1 dosing study conducted with partner Hengrui Pharmaceuticals in China. The company...
Eli Lilly expands infectious disease footprint with up to $3.8B vaccine acquisitions
Eli Lilly agreed to acquire three vaccine companies in deals totaling up to $3.8 billion, pushing further into infectious disease prevention. The transactions include Vaccine Company Inc., Curevo,...
China biotech policy shift as BMS-Hengrui deal sparks Washington scrutiny
A multibillion-dollar licensing alliance between Bristol Myers Squibb and Jiangsu Hengrui has triggered renewed U.S. political pressure on outbound investment rules for biotechnology. House Select...
US and UK regulators clear the way for Genmab’s Tivdak after NICE reverses cost concerns
The UK’s NICE approved reimbursement for Genmab’s tisotumab vedotin (Tivdak) for advanced cervical cancer, reversing earlier cost-effectiveness concerns from the spring. NICE’s updated position...
Cell therapy outsourcing expands as Waypoint Bio raises $20M to run CAR-T trials in China
Waypoint Bio raised $20 million in Series A financing to run multiple CAR-T trials in China, targeting both patient access and study execution through the local clinical environment. The New York...
Verici Dx validates pre-transplant kidney rejection risk signature
Verici Dx validated a 29-gene RNA expression immune signature that predicts acute kidney rejection risk before transplantation, independent of donor characteristics. The company said its next-gen...
Diagnostics and multiomics partnerships expand clinical research capabilities
Panome Bio will expand clinical access to its multiomics services through TD2 Oncology, moving beyond preclinical oncology use into clinical cancer research. The contract research organizations...
Obesity therapeutics move to larger trials after early weight-loss data
Kailera Therapeutics said its triple-acting obesity injection generated double-digit weight loss in a Phase 1 dose-escalation study in China with partner Hengrui Pharmaceuticals. In 12...
FDA delays on AstraZeneca’s camizestrant after negative advisory vote
The FDA extended its decision timeline on AstraZeneca’s oral breast cancer drug camizestrant, following an FDA advisory committee vote against approval for the proposed use. AstraZeneca said the...